HYPERTENSION, PORTAL
Clinical trials for HYPERTENSION, PORTAL explained in plain language.
Never miss a new study
Get alerted when new HYPERTENSION, PORTAL trials appear
Sign up with your email to follow new studies for HYPERTENSION, PORTAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to lower liver vein pressure in cirrhosis patients
Disease control TerminatedThis study tested whether the drug Avenciguat, taken alone or with empagliflozin, can lower high blood pressure in the portal vein (the main vessel to the liver) in people with cirrhosis. About 90 adults with cirrhosis from hepatitis or fatty liver disease were enrolled. The tria…
Matched conditions: HYPERTENSION, PORTAL
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC
-
Experimental pill avenciguat targets liver blood pressure in cirrhosis – but trial halted early
Disease control TerminatedThis study tested a drug called Avenciguat in adults with liver cirrhosis and high blood pressure in the portal vein (the main vessel to the liver). Participants took either a low or high dose of Avenciguat or a placebo twice daily for 24 weeks. The goal was to see if the drug co…
Matched conditions: HYPERTENSION, PORTAL
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 26, 2026 12:44 UTC